Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells

被引:0
作者
Tahereh Hojjatipour
Zahra Sharifzadeh
Amirhosein Maali
Mehdi Azad
机构
[1] Tehran University of Medical Sciences,Department of Hematology and Blood Transfusion, Students Research Center, School of Allied Medicine
[2] Pasteur Institute of Iran,Department of Immunology
[3] Qazvin University of Medical Sciecnes,Department of Medical Biotechnology, Faculty of Allied Medicine
[4] Qazvin University of Medical Sciences,Department of Medical Laboratory Sciences, School of Paramedicine, Faculty of Allied Medicine
来源
Human Cell | 2023年 / 36卷
关键词
CAR-NK cells; Cancer immunotherapy; Chimeric antigen receptors; NK cell; Adoptive cellular therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Natural killer (NK) cells are a critical component of innate immunity, particularly in initial cancer recognition and inhibition of additional tumor growth or metastasis propagation. NK cells recognize transformed cells without prior sensitization via stimulatory receptors and rapidly eradicate them. However, the protective tumor microenvironment facilitates tumor escaping via induction of an exhaustion state in immune cells, including NK cells. Hence, genetic manipulation of NK cells for specific identification of tumor-associated antigens or a more robust response against tumor cells is a promising strategy for NK cells’ tumoricidal augmentation. Regarding the remarkable achievement of engineered CAR-T cells in treating hematologic malignancies, there is evolving interest in CAR-NK cell recruitment in cancer immunotherapy. Innate functionality of NK cells, higher safety, superior in vivo maintenance, and the off-the-shelf potential move CAR-NK-based therapy superior to CAR-T cells treatment. In this review, we have comprehensively discussed the recent genetic manipulations of CAR-NK cell manufacturing regarding different domains of CAR constructs and their following delivery systems into diverse sources of NK cells. Then highlight the preclinical and clinical investigations of CAR-NK cells and examine the current challenges and prospects as an optimistic remedy in cancer immunotherapy.
引用
收藏
页码:1843 / 1864
页数:21
相关论文
共 245 条
  • [1] Weber EW(2020)The emerging landscape of immune cell therapies Cell 181 46-62
  • [2] Maus MV(2015)Short view of leukemia diagnosis and treatment in Iran Int J Hematol-Oncol Stem Cell Res 9 88-1197
  • [3] Mackall CL(2017)Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts EMBO Mol Med 9 1183-594
  • [4] Azad M(2019)Limitations in the design of chimeric antigen receptors for cancer therapy Cells 8 472-527
  • [5] Hartmann J(2019)CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy Front Immunol 10 2683-12
  • [6] Stoiber S(2021)Chimeric antigen receptor-T cells: a pharmaceutical scope Front Pharmacol 12 720692-1471
  • [7] Burger MC(2022)FDA approval summary: axicabtagene ciloleucel for relapsed or refractory follicular lymphoma Oncologist 27 587-144
  • [8] Hernández-López A(2021)Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany Gene Ther 28 513-664
  • [9] Bouchkouj N(2021)US Food and Drug Administration approves Bristol Myers Squibb's and Bluebird Bio's Abecma (idecabtagene vicleucel), the first anti-Bcma car T cell therapy for relapsed or refractory multiple myeloma Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple survival 5 11-114
  • [10] Albinger N(2022)sBCMA plasma level dynamics and anti-BCMA CAR-T-Cell treatment in relapsed multiple myeloma Curr Issues Mol Biol 44 1463-579